Impact of Prior Immune Checkpoint Inhibitor Treatment on the Efficacy of Weekly Paclitaxel and Cetuximab in Recurrent or Metastatic Head and Neck Cancer.
AIM The optimal treatment sequence involving immune checkpoint inhibitors (ICIs) and chemotherapy for recurrent or metastatic head and neck cancer remains unclear. This study aimed to evaluate the efficacy of weekly paclitaxel and cetuximab (PTX + Cmab) following prior ICI treatment. METHODS We retrospectively analyz...